Vanda Pharmaceuticals Advances Tradipitant for Motion Sickness Amid FDA Review Challenges

Vanda Pharmaceuticals Advances Tradipitant for Motion Sickness

Vanda Pharmaceuticals Inc. is making significant strides in the development of tradipitant, a potential treatment for motion sickness, as it navigates regulatory challenges with the U.S. Food and Drug Administration (FDA). Recently, the FDA has requested a brief extension for the expedited re-review of a partial clinical hold that affects long-term studies of tradipitant. This extension pushes the completion date from November 26, 2025, to December 5, 2025. This request comes in light of recent transitions within the FDA’s Center for Drug Evaluation and Research (CDER), which could influence the pace at which tradipitant can advance through clinical testing.

Despite the partial hold, Vanda remains optimistic about tradipitant's future. The review of Vanda's New Drug Application (NDA) is proceeding as planned, with a target action date set for December 30, 2025. Notably, discussions regarding the proposed labeling for tradipitant have commenced, marking a critical step toward potentially delivering the first new pharmacological treatment for motion sickness in over four decades. Such developments are crucial, as effective therapies for motion sickness have been limited, and tradipitant could fill a significant gap in treatment options for patients suffering from this condition.

Tradipitant, a neurokinin-1 receptor antagonist originally licensed from Eli Lilly and Company, is not only being examined for motion sickness but is also under development for other conditions, including gastroparesis and nausea induced by GLP-1 receptor agonists. Vanda Pharmaceuticals is dedicated to addressing high unmet medical needs through innovative therapies, and its proactive engagement with the FDA signifies a commitment to improving patient lives. As Vanda navigates these regulatory processes, the outcomes could have profound implications for the company’s position in the healthcare landscape and its ability to bring new treatments to market.

In addition to the promising updates on tradipitant, Vanda's ongoing focus on innovative therapeutics highlights its strategic importance in the pharmaceutical industry. The company's dedication to tackling unmet medical needs resonates with stakeholders and underscores its potential impact on patient care. As the review process unfolds, both Vanda Pharmaceuticals and those awaiting new treatment options for motion sickness remain hopeful for positive developments that could reshape therapeutic landscapes.